Early eculizumab treatment improves renal outcomes in pediatric lupus nephritis with thrombotic microangiopathy

Nephrology Dialysis Transplantation 2026

View at publisher
Authors: Shihan Yu, Jie Zhang, Jia He, Weijie Kang, Jiayao Shen, Chenxing Zhang, Zhengyu Zhou, Wei Zhou, Lei Yin, Youying Mao
DOI: 10.1093/ndt/gfag031
Cited by: 1
References: 28

Abstract

BACKGROUND: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease. Patients with lupus nephritis (LN) complicated by thrombotic microangiopathy (TMA) exhibit high mortality and poor renal outcomes. Eculizumab, a humanized monoclonal antibody inhibiting terminal complement C5 activation, has been recommended for the treatment of TMA caused by alternative complement pathway activation. This study evaluated the clinical efficacy of eculizumab in pediatric LN-associated TMA. METHODS: We retrospectively analyzed children diagnosed with LN-TMA from July 2009 to January 2025. All patients met the 2019 EULAR/ACR SLE classification criteria and were aged

Fields of Study & Subjects

Complement system in diseases Systemic Lupus Erythematosus Research Renal Diseases and Glomerulopathies

Publication details

Journal / source
Nephrology Dialysis Transplantation
Publisher
Oxford University Press (OUP)
Volume
41
Issue
9
Pages
1665–1672
Publication date
12 February 2026
Language
EN